An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis
brief summary
The purpose of this study is to evaluate long-term safety and efficacy of ublituximab therapy in participants with relapsing multiple sclerosis (RMS).
detailed description
TG1101-RMS303 is an open-label, single-arm extension study designed to evaluate long-term safety and efficacy of ublituximab in participants with RMS. Participants who complete the 96-week, double-blind treatment period of TG1101-RMS301 (RMS301 \[NCT03277261\]) or TG1101-RMS302 (RMS302 \[NCT03277248\]) are eligible for participation in this Open Label Extension (OLE) study. Participants may also be eligible for TG1101-RMS303 if they have completed Week 208 of TG1101-RMS201E (RMS201E \[NCT03381170\]) (United States of America \[USA\] participants only).
official title
An Open Label Extension Study of Ublituximab in Subjects With Relapsing Multiple Sclerosis